Bresch has overseen a lot of drama at generic-drug maker Mylan in her nearly four years as CEO. After acquiring part of Abbott Laboratories earlier this year, Bresch moved the $7.7 billion Mylan to the Netherlands in a controversial “tax inversion” play, then thwarted a plan from Israel-based Teva to buy Mylan for $40 billion. Now Bresch is trying her own hostile takeover of Ireland-based Perrigo.
Read more about Heather Bresch in “Why Wall Street loves to hate Mylan’s CEO.”
|Market Value (as of 9/1/15)|